AVCT Avacta Group Plc
68.00GBp-5.56%Mkt Cap: 337.75M $P/E: —Today
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug co…
Industry Peers
Biotechnology$127.24BUSDP/E 29.3
$76.05BUSDP/E 18.3
$74.84BUSD
$56.77BUSDP/E 37.1
$58.21BUSDP/E 35.5
$41.93BUSDP/E 17.9
$42.84BUSD
$41.27BUSDP/E 64.9
$32.61BUSDP/E 30.0
$29.97BUSDP/E 37.8
$25.66BUSD
$24.05BUSD
$23.24BUSDP/E 29.8
$22.98BUSD
$22.23BUSDP/E 30.6
$22.85BUSDP/E 14.4
$15.02BUSDP/E 15.9
$14.87BUSDP/E 17.3
$14.45BUSDP/E 18.4
$13.81BUSD
| Headline | Source | Time |
|---|---|---|
Yesterday | ||
VVox Markets | ||
This week | ||
Older | ||
AAvacta Therapeutics | ||
VVox Markets | ||
AAvacta Therapeutics | ||
AAvacta Therapeutics | ||
AAvacta Therapeutics | ||